Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET: Tasimelteon Maintenance in N24HSWD
NCT01430754Phase 3Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Sep 2011
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tasimelteon in Non-24-hour sleep-wake disorder (N24SWD), sponsored by Vanda Pharmaceuticals Inc.. Started Sep 2011; status: completed.
02
Drugs
tasimelteon
03
Conditions
Non-24-hour sleep-wake disorder (N24SWD)
Beyond the preview
Go deeper on NCT01430754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01430754.